Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma

Rolf W Sparidans; Hilde Rosing; Johannes J M Rood; Jan H M Schellens; Jos H Beijnen

doi:10.1016/j.jchromb.2016.09.012

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma

Rolf W Sparidans, Hilde Rosing, Johannes J M Rood, Jan H M Schellens, Jos H Beijnen

Pharmacoepidemiology and Clinical Pharmacology

MC Slotervaart

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	390-398
Number of pages	9
Journal	Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume	1033-1034
DOIs	https://doi.org/10.1016/j.jchromb.2016.09.012
Publication status	Published - 15 Oct 2016

Keywords

Afatinib
Erlotinib
Gefitinib
Encorafenib
LC MS/MS
Plasma

Access to Document

10.1016/j.jchromb.2016.09.012

liquidFinal published version, 786 KBLicence: Taverne

Cite this

Sparidans, R. W., Rosing, H., Rood, J. J. M., Schellens, J. H. M., & Beijnen, J. H. (2016). Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1033-1034, 390-398. https://doi.org/10.1016/j.jchromb.2016.09.012

Sparidans, Rolf W ; Rosing, Hilde ; Rood, Johannes J M et al. / Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2016 ; Vol. 1033-1034. pp. 390-398.

@article{45ab0c9975904a1c99867cc3c9a9467b,

title = "Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma",

keywords = "Afatinib, Erlotinib, Gefitinib, Encorafenib, LC MS/MS, Plasma",

author = "Sparidans, {Rolf W} and Hilde Rosing and Rood, {Johannes J M} and Schellens, {Jan H M} and Beijnen, {Jos H}",

year = "2016",

month = oct,

day = "15",

doi = "10.1016/j.jchromb.2016.09.012",

language = "English",

volume = "1033-1034",

pages = "390--398",

journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",

issn = "1570-0232",

publisher = "Elsevier",

}

Sparidans, RW, Rosing, H, Rood, JJM, Schellens, JHM & Beijnen, JH 2016, 'Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1033-1034, pp. 390-398. https://doi.org/10.1016/j.jchromb.2016.09.012

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. / Sparidans, Rolf W; Rosing, Hilde; Rood, Johannes J M et al.
In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1033-1034, 15.10.2016, p. 390-398.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma

AU - Sparidans, Rolf W

AU - Rosing, Hilde

AU - Rood, Johannes J M

AU - Schellens, Jan H M

AU - Beijnen, Jos H

PY - 2016/10/15

Y1 - 2016/10/15

KW - Afatinib

KW - Erlotinib

KW - Gefitinib

KW - Encorafenib

KW - LC MS/MS

KW - Plasma

U2 - 10.1016/j.jchromb.2016.09.012

DO - 10.1016/j.jchromb.2016.09.012

M3 - Article

C2 - 27639128

SN - 1570-0232

VL - 1033-1034

SP - 390

EP - 398

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

ER -

Sparidans RW, Rosing H, Rood JJM, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2016 Oct 15;1033-1034:390-398. doi: 10.1016/j.jchromb.2016.09.012